Urogen Pharma (NASDAQ:URGN – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Institutional & Insider Ownership
91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 4.7% of Urogen Pharma shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Urogen Pharma and Gilead Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Urogen Pharma | $109.79 million | 13.26 | -$153.49 million | ($2.75) | -10.87 |
| Gilead Sciences | $29.44 billion | 5.50 | $8.51 billion | $7.34 | 17.78 |
Gilead Sciences has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Urogen Pharma has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Profitability
This table compares Urogen Pharma and Gilead Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -94.83% | N/A | -62.85% |
| Gilead Sciences | 30.99% | 48.19% | 18.28% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Urogen Pharma and Gilead Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 7 | 1 | 2.80 |
| Gilead Sciences | 0 | 4 | 25 | 0 | 2.86 |
Urogen Pharma currently has a consensus target price of $36.67, suggesting a potential upside of 22.71%. Gilead Sciences has a consensus target price of $156.93, suggesting a potential upside of 20.25%. Given Urogen Pharma’s higher probable upside, equities analysts clearly believe Urogen Pharma is more favorable than Gilead Sciences.
Summary
Gilead Sciences beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
